

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**LIMITED REVIEW REPORT AND  
THE INTERIM CONDENSED SEPARATE FINANCIAL  
STATEMENTS  
FOR THE SIX MONTHS PERIOD ENDED  
30 JUNE 2022**

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Interim condensed separate financial statements  
For the six months period ended 30 June 2022**

---

<b>Index</b>	<b>Page</b>
Limited review report	1
Interim condensed separate statement of financial position	2
Interim condensed separate statement of profits or losses	3
Interim condensed separate statement of comprehensive income	4
Interim condensed separate statement of changes in equity	5
Interim condensed separate statement of cash flows	6
Notes to the interim condensed separate financial statements	7 – 22



## Limited Review Report on the Interim Financial Statements

To: The Board of Directors of Cleopatra Hospital Company (S.A.E.)

### Introduction


We conducted our limited review on the accompanying interim condensed separate financial position of Cleopatra Hospital Company (S.A.E.) (the "Company") as at 30 June 2022 and the related interim condensed separate statements of profit or loss, comprehensive income, changes in equity and cash flows for the six months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed separate financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed separate financial statements based on our limited review.

### Scope of the limited review

We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed separate financial statements consists of applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed separate financial statements.

### Conclusion

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed separate financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".

  
  
Tamer Abdel Tawab  
Member of Egyptian Society of Accountants & Auditors  
Member of AICPA  
R.A.A. 17996  
F.R.A. 388

18 August 2022  
Cairo

CLEOPATRA HOSPITAL COMPANY "S.A.E."

Interim condensed separate statement of financial position - At 30 June 2022

(All amounts in Egyptian Pounds)	Note	30 June 2022	31 December 2021
<b>Assets</b>			
<b>Non-current assets</b>			
Fixed assets	5	364,132,021	358,849,938
Right-of-use assets	6	84,015,335	93,348,683
Goodwill		172,587,300	172,587,300
Investments in subsidiaries		1,080,947,170	1,045,947,470
Investments in associates		1,224,990	1,224,990
Paid under investments purchased		24,173,000	5,671,000
<b>Total non-current assets</b>		<b>1,727,079,816</b>	<b>1,677,631,391</b>
<b>Current assets</b>			
Inventories	7	23,862,466	21,813,480
Trade receivables	8	176,850,091	158,999,352
Due from related parties	9/A	61,303,904	89,357,533
Debtors and other debit balances	10	71,329,951	115,699,638
Financial assets at amortized cost - treasury bills	11	-	495,338,060
Cash on hands and at banks	12	50,161,404	75,551,933
<b>Total current assets</b>		<b>383,507,816</b>	<b>926,729,996</b>
<b>Total assets</b>		<b>2,110,587,632</b>	<b>2,604,361,387</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital		800,000,000	800,000,000
Treasury Shares	22	(645,888,947)	(4,152,742)
Retained earnings		1,032,217,380	975,126,950
Employees stock ownership Plan		16,579,882	8,289,941
Reserves		405,326,401	390,707,869
<b>Total equity</b>		<b>1,608,234,716</b>	<b>2,169,972,018</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Lease liabilities	13	90,138,051	95,184,292
Deferred tax liabilities		7,286,252	7,679,698
Purchased investment liability		14,485,000	14,485,000
<b>Total non-current liabilities</b>		<b>111,909,303</b>	<b>117,348,990</b>
<b>Current liabilities</b>			
Banks overdrafts	14	160,148,413	60,627,560
Provisions		7,477,427	8,157,517
Trade payables and other credit balances	15	159,319,111	158,941,199
Due to related parties	9/B	2,955,658	13,979,754
Lease liabilities	13	14,122,548	13,292,019
Current income tax liabilities		46,420,456	62,042,330
<b>Total current liabilities</b>		<b>390,443,613</b>	<b>317,040,379</b>
<b>Total liabilities</b>		<b>502,352,916</b>	<b>434,389,369</b>
<b>Total liabilities and equity</b>		<b>2,110,587,632</b>	<b>2,604,361,387</b>

- The accompanying notes from (1) to (23) are integral part of these separate interim condensed statement financial statements

- Auditor's limited review report is attached

Mr. Ahmed Gamal  
Group CFO

Dr. Ahmed El-Din Mahmoud  
CEO & Managing Director

Mr. Ahmed Adel Badreldin  
Non Executive Chairman

18 August 2022  
Cairo



CLEOPATRA HOSPITAL COMPANY (S.A.E.)

Interim condensed separate statement of profit or loss  
For the six months period ended 30 June 2022

(All amounts in Egyptian Pounds)

	Note	Six months ended 30 June		Three months ended 30 June	
		2022	2021	2022	2021
Operating revenue	16	539,350,414	628,517,065	252,052,139	318,319,478
<b>Less:</b>					
Operating costs	17	(320,477,004)	(345,517,872)	(154,782,617)	(176,125,182)
<b>Gross profit</b>		<b>218,873,410</b>	<b>282,999,193</b>	<b>97,269,522</b>	<b>142,194,296</b>
<b>Add / (Less)</b>					
General and administrative expenses	18	(74,279,639)	(66,812,156)	(35,270,798)	(33,267,087)
Impairment of financial assets	19	(2,827,005)	(18,018,752)	(1,428,501)	(12,208,565)
Provisions		(5,439,166)	(6,758,599)	(4,657,733)	(484,318)
Other income		4,055,428	5,380,832	1,736,975	1,021,119
Aquisition costs		(918,990)	(6,861,358)	(124,468)	(1,553,324)
Finance income		20,928,582	17,599,412	5,914,298	9,033,203
Finance expenses		(9,886,449)	(9,478,732)	(5,973,375)	(5,676,281)
<b>Profit for the period before income tax</b>		<b>150,506,171</b>	<b>198,049,840</b>	<b>57,465,920</b>	<b>99,059,043</b>
Current tax		(32,818,022)	(52,643,477)	(10,533,198)	(27,970,046)
Deferred tax		393,446	2,116,157	(156,487)	1,873,742
<b>Profit after income tax</b>		<b>118,081,595</b>	<b>147,522,520</b>	<b>46,776,235</b>	<b>72,962,739</b>
<b>Earning per share</b>	<b>20</b>	<b>0.08</b>	<b>0.09</b>	<b>0.03</b>	<b>0.05</b>

- The accompanying notes from (1) to (23) are integral part of these separate interim condensed statement financial statements.

**CLEOPATRA HOSPITAL COMPANY (S.A.E.)**

**Interim condensed separate statement of comprehensive income  
For the six months period ended 30 June 2022**

---

(All amounts in Egyptian Pounds)

	<b>Six months ended 30 June</b>		<b>Three months ended 30 June</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Profit for the period	118,081,595	147,522,520	46,776,235	72,962,739
Other comprehensive income	-	-	-	-
<b>Comprehensive income for the period</b>	<b>118,081,595</b>	<b>147,522,520</b>	<b>46,776,235</b>	<b>72,962,739</b>

- The accompanying notes from (1) to (23) are integral part of these separate interim condensed statement financial statements.

**CLEOPATRA HOSPITAL COMPANY (S.A.E.)**

**Interim condensed separate statement of changes in equity  
For the six months period ended 30 June 2022**

(All amounts in Egyptian Pounds)

	Capital	Treasury shares	Reserves	Retained earnings	Employees stock ownership Plan	Total
As previously published	800,000,000	-	369,101,452	744,657,574	-	1,913,759,026
New EAS adoption	-	-	-	(17,793,229)	-	(17,793,229)
<b>Balance at 1 January 2021</b>	<b>800,000,000</b>	<b>-</b>	<b>369,101,452</b>	<b>726,864,345</b>	<b>-</b>	<b>1,895,965,797</b>
Employees and board of directors dividends	-	-	-	(33,174,238)	-	(33,174,238)
Legal reserve	-	-	10,933,804	(10,933,804)	-	-
Treasury shares	-	(46,612,865)	-	-	-	(46,612,865)
Comprehensive income for the period	-	-	-	147,522,520	-	147,522,520
<b>Balance at 30 June 2021</b>	<b>800,000,000</b>	<b>(46,612,865)</b>	<b>380,035,256</b>	<b>830,278,823</b>	<b>-</b>	<b>1,963,701,214</b>
<b>Balance at 1 January 2022</b>	<b>800,000,000</b>	<b>(4,152,742)</b>	<b>390,707,869</b>	<b>975,126,950</b>	<b>8,289,941</b>	<b>2,169,972,018</b>
Dividends for employees	-	-	-	(46,372,633)	-	(46,372,633)
Employees stock ownership Plan	-	-	-	-	8,289,941	8,289,941
Legal reserve	-	-	14,618,532	(14,618,532)	-	-
Treasury shares	-	(641,736,205)	-	-	-	(641,736,205)
Comprehensive income for the period	-	-	-	118,081,595	-	118,081,595
<b>Balance at 30 June 2022</b>	<b>800,000,000</b>	<b>(645,888,947)</b>	<b>405,326,401</b>	<b>1,032,217,380</b>	<b>16,579,882</b>	<b>1,608,234,716</b>

- The accompanying notes from (1) to (23) are integral part of these separate interim condensed statement financial statements.

CLEOPATRA HOSPITAL COMPANY (S.A.E.)

Interim condensed separate statement of cash flows  
For the six months period ended 30 June 2022

(All amounts in Egyptian Pounds)	Note	30 June 2022	30 June 2021
<b>Cash flows from operating activities</b>			
Profit before tax		150,506,171	198,049,840
<b>Adjustments to reconcile net income to cash flows from operating activities</b>			
Fixed assets depreciation	5	24,069,604	19,479,539
Right of use assets depreciation	6	5,387,571	5,784,381
Gain from sale of fixed assets		366,020	(5,913)
Impairment of trade and other receivables	8	(10,641,927)	18,729,354
Impairment of cash	12	11,431	(710,602)
Impairment of inventory	7	(80,137)	136,510
Provisions		5,439,166	6,758,599
Interests and commissions - Overdraft		3,195,434	3,422,255
Interests and commissions - Lease		6,691,015	6,008,085
Interest income		(18,036,451)	(17,599,412)
Employees stock ownership Plan		8,289,942	-
Loss in investments in associates		-	(81,899)
<b>Operating profits before changes in assets and liabilities</b>		<b>175,197,839</b>	<b>239,970,737</b>
<b>Changes in assets and liabilities</b>			
Change in inventories		(1,968,849)	2,797,425
Change in trade receivables		(7,208,811)	(7,017,016)
Change in debtors and other debit balances		48,396,043	13,987,384
Change in due from related parties		(1,946,371)	(755,330)
Change in creditors and other credit balances		(3,571,310)	(990,640)
Change in due to related parties		(11,024,096)	-
Provision utilized		(6,119,254)	(6,713,372)
Tax paid		(48,439,896)	(33,968,288)
<b>Net cash flows generated from / (used in) operating activities</b>		<b>143,315,295</b>	<b>207,310,900</b>
<b>Cash flows from investing activities</b>			
Payments for purchase of fixed assets		(13,806,270)	(18,093,214)
Payments for projects under construction		(16,353,532)	(10,866,640)
Proceeds from sale of fixed assets		442,104	156,100
Advance payment for purchase of fixed assets		(4,056,359)	(5,485,955)
Payments under long-term investments		(18,500,000)	(305,687,787)
Payments under investments in subsidiaries		(34,999,720)	-
Interests received		18,036,451	13,149,026
<b>Net cash flows used in investing activities</b>		<b>(69,237,326)</b>	<b>(326,828,470)</b>
<b>Cash flows from financing activities</b>			
Lease liabilities payments		(242,881)	(12,327,275)
Proceeds from bank overdraft		597,009,334	219,261,355
Payments for bank overdraft		(497,488,482)	(3,263,754)
Interests and commissions paid		(8,992,910)	(80,811,495)
Treasury shares		(641,736,202)	(46,612,865)
Dividends paid		(43,343,986)	(32,687,466)
<b>Net cash flows generated from / (used in) financing activities</b>		<b>(594,795,127)</b>	<b>43,558,500</b>
<b>Change in cash and cash equivalents during the period</b>		<b>(520,717,158)</b>	<b>(75,959,070)</b>
Cash and cash equivalents at the beginning of the period		571,297,568	274,007,267
<b>Cash and cash equivalents at the end of the period</b>	12	<b>50,580,410</b>	<b>198,048,197</b>

- The accompanying notes from (1) to (23) are integral part of these separate interim condensed statement financial statements.



## **CLEOPATRA HOSPITAL COMPANY "S.A.E."**

### **Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### **1. Introduction**

Cleopatra Hospital Company (Lasheen and Partners) was established as a limited partnership on 19 July 1979. The decision of the Chairman of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of the Company from a "limited partnership" into Cleopatra Hospital Company "S.A.E." in accordance with the provisions of Law No. (8) Of 1997 and Law No. (95) Of 1992. The company is listed on the Egyptian stock exchange.

The purpose of the Company is to establish a private hospital with the aim to offer modern and high quality medical services and provide medical care and treatment for patients. The Company may have interest or participate in any manner in companies or other firms which carry on similar activities in Egypt or abroad, The Company may acquire, merge or affiliate such entities.

The Company is located at 39 and 41 Cleopatra Street, Heliopolis, Cairo.

These separate interim financial statements have been approved for issuance by the management of the Company on the 18 August 2022.

#### **2. Basis of preparation**

##### **A. Statement of compliance**

This interim condensed separate financial statements for the three-month reporting period ended 30 June 2022 have been prepared in accordance with Egyptian Accounting Standard 30 "Interim Financial Reporting".

This interim condensed separate financial information does not include all the notes of the type normally included in an annual financial statement. Accordingly, this interim condensed separate financial information is to be read in conjunction with the annual financial statement for the year ended 31 December 2021.

The accounting policies adopted in the preparation of this interim condensed separate financial information are consistent with those of the previous financial year and corresponding interim reporting period.

##### **B. Functional and presentation currency**

Items included in the interim condensed separate financial statements are measured using the currency of the primary economic environment in which the Company operates ('the functional currency'), The Company's interim condensed separate financial statements are presented in Egyptian Pounds, which is the Company's functional and presentation currency.

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### C. Use of estimates and judgements

The preparation of interim condensed separate financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

The significant judgments made by management in applying the Company's accounting policies and key sources of estimation uncertainty were the same as those described in the last consolidated financial statements as at and for the year ended 31 December 2021.

#### 3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Company. The senior management is represented in Company's executive management committee. The segment reports are provided to the Company based on each company, as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the period ended 30 June 2022 for each segment:

	<b>Cleopatra Hospital Company</b>	<b>Queens Hospitals</b>	<b>Al Kateb Hospitals</b>	<b>Consolidated adjustments</b>	<b>Total</b>
<u>Statement of financial position</u>					
Non-current assets	1,520,220,308	69,365,267	137,494,241	-	1,727,079,816
Current assets	347,847,154	84,394,614	36,772,622	(85,506,574)	383,507,816
<b>Total assets</b>	<b>1,868,067,462</b>	<b>153,759,881</b>	<b>174,266,863</b>	<b>(85,506,574)</b>	<b>2,110,587,632</b>
Current liabilities	407,421,038	33,995,657	34,533,491	(85,506,573)	390,443,613
Non-current liabilities	40,986,542	67,467,395	3,455,366	-	111,909,303
<b>Total Liabilities</b>	<b>448,407,580</b>	<b>101,463,052</b>	<b>37,988,857</b>	<b>(85,506,573)</b>	<b>502,352,916</b>
<u>Statement of profit or loss:</u>					
Operating revenue	491,444,933	30,392,911	17,512,570	-	539,350,414
Operating costs	(276,251,845)	(18,884,860)	(25,340,299)	-	(320,477,004)
<b>Gross profit</b>	<b>215,193,088</b>	<b>11,508,051</b>	<b>(7,827,729)</b>	<b>-</b>	<b>218,873,410</b>
Other expenses and revenues	(89,214,079)	(5,254,538)	(6,323,198)	-	(100,791,815)
<b>Profit for period</b>	<b>125,979,009</b>	<b>6,253,513</b>	<b>(14,150,927)</b>	<b>-</b>	<b>118,081,595</b>
<u>Other Items</u>					
Capital expenditure	25,645,195	365,943	4,148,662	-	30,159,800
Fixed assets depreciation	18,559,437	1,646,759	3,863,407	-	24,069,603

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 3- Segment reporting (continued)

Below is a summary of each segment, which is presented for the year ended 31 December 2021 for each segment:

	Cleopatra Hospital Company	Queens Hospitals	Al Kateb Hospitals	Consolidated adjustments	Total
<u>Statement of financial position</u>					
Non-current assets	1,469,974,647	72,791,123	134,865,621	-	1,677,631,391
Current assets	791,225,113	106,725,556	63,940,470	(35,161,143)	926,729,996
<b>Total assets</b>	<b>2,261,199,760</b>	<b>179,516,679</b>	<b>198,806,091</b>	<b>(35,161,143)</b>	<b>2,604,361,387</b>
Current liabilities	241,753,084	66,870,655	43,577,783	(35,161,143)	317,040,379
Non-current liabilities	47,363,324	66,602,710	3,382,956	-	117,348,990
<b>Total Liabilities</b>	<b>289,116,408</b>	<b>133,473,365</b>	<b>46,960,739</b>	<b>(35,161,143)</b>	<b>434,389,369</b>
<u>Statement of profit or loss:</u>					
Operating revenue	935,166,243	164,383,486	110,217,897	-	1,209,767,626
Operating costs	(523,192,530)	(77,718,776)	(77,201,230)	-	(678,112,536)
<b>Gross profit</b>	<b>411,973,713</b>	<b>86,664,710</b>	<b>33,016,667</b>	<b>-</b>	<b>531,655,090</b>
Other expenses and revenues	(184,257,324)	(33,963,941)	(21,063,178)	-	(239,284,443)
<b>Profit for year</b>	<b>227,716,389</b>	<b>52,700,769</b>	<b>11,953,489</b>	<b>-</b>	<b>292,370,647</b>
<u>Other Items</u>					
Capital expenditure	57,220,004	2,830,097	8,004,500	-	68,054,601
Fixed assets depreciation	34,827,246	3,171,302	3,987,360	-	41,985,908

Below is a summary of each segment, which is presented for the year ended 30 June 2021 for each segment:

	Cleopatra Hospital	Queens Hospital	El Kateb Hospital	Consolidated adjustment	Total
<u>Statement of financial position</u>					
Non-current assets	1,583,405,146	75,853,190	9,675,085	-	1,668,933,421
Current assets	675,877,875	94,196,036	66,254,303	(50,919,431)	785,408,783
<b>Total assets</b>	<b>2,259,283,021</b>	<b>170,049,226</b>	<b>75,929,388</b>	<b>(50,919,431)</b>	<b>2,454,342,204</b>
Current liabilities	301,317,508	78,853,649	38,190,635	(50,919,367)	367,442,425
Non-current liabilities	51,976,519	67,135,107	4,086,939	-	123,198,565
<b>Total Liabilities</b>	<b>353,294,027</b>	<b>145,988,756</b>	<b>42,277,574</b>	<b>(50,919,367)</b>	<b>490,640,990</b>
<u>Statement of profit or loss:</u>					
Operating revenue	450,063,217	102,253,604	76,200,244	-	628,517,065
Operating costs	(253,253,110)	(45,322,123)	(46,942,639)	-	(345,517,872)
<b>Gross profit</b>	<b>196,810,107</b>	<b>56,931,481</b>	<b>29,257,605</b>	<b>-</b>	<b>282,999,193</b>
Other expenses and revenues	(93,879,159)	(26,213,557)	(15,383,957)	-	(135,476,673)
<b>Profit for period</b>	<b>102,930,948</b>	<b>30,717,924</b>	<b>13,873,648</b>	<b>-</b>	<b>147,522,520</b>
<u>Other Items</u>					
Capital expenditure	25,993,585	1,054,621	1,911,648	-	28,959,854
Fixed assets depreciation	14,789,169	1,501,133	3,189,237	-	19,479,539

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 4. Financial assets and financial liabilities

The Company holds the following financial instruments:

	Amortised cost	
	30 June 2022	31 December 2021
<b>Financial assets</b>		
Trade receivables	212,057,027	204,848,215
Due from related parties	61,303,904	59,357,533
Debtors and other debit balances *	7,609,100	11,112,000
Financial assets at amortized cost -Treasury Bills	-	495,338,060
Cash on hand and at banks	50,580,410	75,959,508
	<b>331,550,441</b>	<b>842,615,316</b>

\* Excluding prepayments, advance to suppliers and withholding taxes.

	Amortised cost	
	30 June 2022	31 December 2021
<b>Financial Liabilities</b>		
Creditors and other credit balances **	157,287,458	157,283,223
Lease liabilities	104,260,599	108,476,311
Bank's overdraft	160,148,413	60,627,560
Due to Related Parties	2,955,658	13,979,754
	<b>424,652,128</b>	<b>340,366,848</b>

\*\* Excluding social insurance.

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Notes to the interim condensed separate financial statements - For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**5. Fixed assets**

	Lands	Machinery, equipment and devices	Tools and instruments	Furniture	Buildings	Vehicles	Computers	Leasehold improvements	Projects under construction	Total
<b>At 1 January 2021</b>										
Cost	82,878,000	207,850,428	10,158,230	16,474,127	79,922,798	10,828,365	40,372,806	29,654,807	8,892,633	487,032,194
Accumulated depreciation	-	(84,180,598)	(5,873,606)	(8,079,757)	(29,691,924)	(3,226,282)	(15,608,770)	(6,316,355)	-	(152,977,292)
<b>Net book value</b>	<b>82,878,000</b>	<b>123,669,830</b>	<b>4,284,624</b>	<b>8,394,370</b>	<b>50,230,874</b>	<b>7,602,083</b>	<b>24,764,036</b>	<b>23,338,452</b>	<b>8,892,633</b>	<b>334,054,902</b>
<b>Year ended 31 December 2021</b>										
Opening balance at the beginning of the year	82,878,000	123,669,830	4,284,624	8,394,370	50,230,874	7,602,083	24,764,036	23,338,452	8,892,633	334,054,902
Additions	-	24,853,588	1,114,150	7,819,430	-	3,092,000	10,722,488	507,481	19,945,466	68,054,603
Disposals	-	(2,372,415)	(289,718)	(222,310)	-	-	-	-	-	(2,884,443)
Transfers from projects under construction	-	1,658,725	1,596,624	10,133	9,416,761	-	432,283	11,344,183	(24,458,709)	-
Depreciation for the year	-	(18,211,075)	(1,138,279)	(2,681,511)	(2,828,206)	(2,427,909)	(10,319,018)	(4,379,911)	-	(41,985,909)
Accumulated depreciation of disposal	-	1,098,780	289,718	222,297	-	-	-	-	-	1,610,795
<b>Balance at 31 December 2021</b>	<b>82,878,000</b>	<b>130,697,433</b>	<b>5,857,119</b>	<b>13,542,409</b>	<b>56,819,429</b>	<b>8,266,174</b>	<b>25,599,789</b>	<b>30,810,205</b>	<b>4,379,390</b>	<b>358,849,948</b>
<b>At 31 December 2021</b>										
Cost	82,878,000	231,990,326	12,579,286	24,081,380	89,339,559	13,920,365	51,527,577	41,506,471	4,379,390	552,202,354
Accumulated depreciation	-	(101,292,893)	(6,722,167)	(10,538,971)	(32,520,130)	(5,654,191)	(25,927,788)	(10,696,266)	-	(193,352,406)
<b>Net book amount</b>	<b>82,878,000</b>	<b>130,697,433</b>	<b>5,857,119</b>	<b>13,542,409</b>	<b>56,819,429</b>	<b>8,266,174</b>	<b>25,599,789</b>	<b>30,810,205</b>	<b>4,379,390</b>	<b>358,849,948</b>
<b>At 30 June 2022</b>										
Opening balance at the beginning of the period	82,878,000	130,697,433	5,857,119	13,542,409	56,819,429	8,266,174	25,599,789	30,810,205	4,379,390	358,849,948
Additions	-	4,892,842	1,313,740	3,622,972	-	-	2,794,168	1,182,549	16,353,531	30,159,802
Disposals	-	(500,000)	-	-	-	(770,000)	-	-	-	(1,270,000)
Transfers from projects under construction	-	-	-	86,568	1,215,349	-	1,201,145	-	(2,503,062)	-
Depreciation for the period	-	(9,801,860)	(599,525)	(1,749,857)	(1,727,959)	(2,438,453)	(5,134,950)	(2,617,000)	-	(24,069,604)
Accumulated depreciation of disposal	-	125,000	-	-	-	336,875	-	-	-	461,875
<b>Balance at 30 June 2022</b>	<b>82,878,000</b>	<b>125,413,415</b>	<b>6,571,334</b>	<b>15,502,092</b>	<b>56,306,819</b>	<b>5,394,596</b>	<b>24,460,152</b>	<b>29,375,754</b>	<b>18,229,859</b>	<b>364,132,021</b>
Cost	82,878,000	236,383,168	13,893,026	27,790,920	90,554,908	13,150,365	55,522,890	42,689,020	18,229,859	581,092,156
Accumulated depreciation	-	(110,969,753)	(7,321,692)	(12,288,828)	(34,248,089)	(7,755,769)	(31,062,738)	(13,313,266)	-	(216,960,135)
<b>Net book value at period end</b>	<b>82,878,000</b>	<b>125,413,415</b>	<b>6,571,334</b>	<b>15,502,092</b>	<b>56,306,819</b>	<b>5,394,596</b>	<b>24,460,152</b>	<b>29,375,754</b>	<b>18,229,859</b>	<b>364,132,021</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 6. Right of use asset

The right of use represents lease contracts related to buildings and was measured at a carrying amount as if the standard had been applied since the inception of the lease but discounted using the incremental borrowing rate to the lessee at the date of application, and it is subsequently amortized over the life of the lease using the straight line method.

	<u>30 June 2022</u>	<u>31 December 2021</u>
<b>Buildings</b>		
Balance at the beginning of the period / year	93,348,683	-
The impact of the first adoption standard no. 49 "Lease Contracts"	-	102,673,541
Adjustments	(3,945,777)	
Additions during the period / year	-	2,132,533
Amortization during the period / year	<u>(5,387,571)</u>	<u>(11,457,391)</u>
<b>Balance</b>	<u><b>84,015,335</b></u>	<u><b>93,348,683</b></u>

Lease payments are discounted at an incremental borrowing rate in the lease. If this rate cannot be determined, then the borrowing rate of the lessee is used, which is the rate that the lessee would have to pay to borrow the money needed to obtain an asset of similar value in a similar economic environment with similar terms and conditions. An average interest rate of 11.15% has been used.

#### 7. Inventories

	<u>30 June 2022</u>	<u>31 December 2021</u>
Medical supply inventory	12,249,379	10,570,455
Medicine inventory	9,378,636	9,331,382
Maintenance and spare parts inventory	964,056	1,063,951
Stationary inventory	615,948	518,167
Hospitality inventory	596,648	390,428
Food and beverage inventory	111,243	72,678
	<u><b>23,915,910</b></u>	<u><b>21,947,061</b></u>
Less: Impairment of inventory	<u>(53,444)</u>	<u>(133,581)</u>
	<u><b>23,862,466</b></u>	<u><b>21,813,480</b></u>

Movement in the provision for inventory is as follows:

	<u>30 June 2022</u>	<u>31 December 2021</u>	<u>30 June 2021</u>
Balance at the beginning of the period / year	133,581	115,285	115,285
Provisions formed during the period / year	-	360,550	143,007
Provisions no longer required during the period / year	(80,137)	(160,557)	(6,497)
Used during the year	-	(181,697)	-
<b>Balance at the end of the year</b>	<u><b>53,444</b></u>	<u><b>133,581</b></u>	<u><b>251,795</b></u>

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 8. Trade receivables

	<u>30 June 2022</u>	<u>31 December 2021</u>
Due from customers	207,209,659	201,039,753
Income from inpatients	4,847,368	3,808,462
	<u>212,057,027</u>	<u>204,848,215</u>
<b>Less:</b>		
Expected credit losses in the trade receivables balances	(35,206,936)	(45,848,863)
	<u>176,850,091</u>	<u>158,999,352</u>

The income from inpatients comprises the revenues that have not been billed at the financial position date for their stay while the procedures of the medical services have not been completed.

The Company applies the EAS 47 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the payment profiles of customers over a period of 36 month before each balance sheet date and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Company has identified the GDP and the unemployment rate of the countries in which it sells its goods and services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors.

The credit loss allowance for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days that an asset is past due, with adjusting it.

	<u>30 June 2022</u>			
	<u>Loss Rate</u>	<u>Gross carrying amount</u>	<u>Lifetime ECL</u>	<u>Net carrying value</u>
<b><u>Trade receivables</u></b>				
- Current until less than 30 days overdue	0.5%	145,378,530	752,636	144,625,894
- 30 to 60 days overdue	4%	10,674,634	420,586	10,254,048
- 61 to 90 days overdue	8%	7,077,226	563,420	6,513,806
- 91 to 120 days overdue	15%	7,595,665	1,150,760	6,444,905
- 121 to 360 days overdue	43%	14,776,907	6,424,985	8,351,922
- 361 to 720 days overdue	60%	1,657,551	998,035	659,516
- More than 720 days	100%	24,896,514	24,896,514	-
<b>Total</b>		<u>212,057,027</u>	<u>35,206,936</u>	<u>176,850,091</u>

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Notes to the interim condensed separate financial statements  
For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**Trade receivables (continued)**

	Loss rate	31 December 2021		
		Gross carrying amount	Lifetime ECL	Net carrying value
<b>Trade receivables</b>				
- Current until less than 30 days overdue	1%	125,261,394	1,223,555	124,037,839
- 30 to 60 days overdue	6%	19,622,547	1,206,112	18,416,435
- 61 to 90 days overdue	13%	10,053,403	1,351,196	8,702,207
- 91 to 120 days overdue	28%	4,726,985	1,317,034	3,409,951
- 121 to 360 days overdue	64%	11,392,966	7,304,641	4,088,325
- 361 to 720 days overdue	87%	2,694,382	2,349,787	344,595
- More than 720 days	100%	31,096,538	31,096,538	-
<b>Total</b>		<b>204,848,215</b>	<b>45,848,863</b>	<b>158,999,352</b>

Movement in the provision for trade receivables impairments is as follows:

	30 June 2022	31 December 2021	30 June 2021
Balance at the beginning of the period / year	45,848,863	43,959,355	43,959,355
The impact of the first adoption standard no.47 "Financial Instruments"	-	4,940,868	4,940,868
Provisions formed during the period / year	6,440,173	44,383,734	34,059,376
Provision used during the period / year	(13,457,499)	(22,173,459)	-
Provision no longer required during period /year	(3,624,601)	(25,261,635)	(15,330,022)
<b>Ending balance at the end of period / year</b>	<b>35,206,936</b>	<b>45,848,863</b>	<b>67,629,577</b>



## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 9. Related Parties Transactions

During the period / year the Company made transactions with certain related parties. The Balances with related parties at the interim financial statements date as well as the transactions during the period / year were as follows:

##### A. Due from related parties

<u>Company name</u>	<u>Nature of transaction</u>	<u>Transaction value</u>	<u>30 June 2022</u>	<u>31 December 2021</u>
Nile Badrawi Hospital (Subsidiary)	The Group's share of the company's expenses *	7,870,380	-	-
	Income from medical activity	1,034,178	-	-
	Expense from medical activity	51,041	-	-
Cairo Specialised Hospital (Subsidiary)	The Group's share of the company's expenses *	10,540,934	-	-
	Expense from medical activity	1,061,802	-	-
	Income from medical activity	3,926,643	-	-
	Other Income (Rents)	31,920	-	-
Al Shorouk Hospital (Subsidiary)	The Group's share of the company's expenses *	9,568,352	-	-
	Expense from medical activity	338,127	-	-
	Income from medical activity	861,942	-	-
CHG for Medical Service (Subsidiary)	Expenses on behalf of the company	(1,029,544)	53,258,572	54,288,116
	Income from medical activity			-
CHG Pharma for Pharmacies Management (Subsidiary)	Expenses on behalf of the company	14,934	3,116,041	3,101,107
Other parties	Expenses on behalf of related parties	1,352,528	1,696,347	343,820
	The Group's share of the company's expenses *	1,652,784	3,232,944	1,624,490
			<u>61,303,904</u>	<u>59,357,533</u>

##### B. Due to related parties

<u>Company name</u>	<u>Nature of transaction</u>	<u>Transaction value</u>	<u>30 June 2022</u>	<u>31 December 2021</u>
CHG for Hospitals	Management fees		2,955,658	13,979,754
			<u>2,955,658</u>	<u>13,979,754</u>

- During 2017, Cleopatra Hospital Company signed an agreement with its subsidiaries. Under this contract, the company distributes the costs of joint activities to the group companies according to the percentages related to the revenues generated by each company. This agreement has been approved by the boards of directors of the group companies and their general assemblies.
- Transactions with related parties are through buying, selling or exchanging services. Prices, policies and conditions related to these operations have been approved by the company's management and follow the same principles as dealing with others.

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 10. Debtors and other debit balances

	<u>30 June 2022</u>	<u>31 December 2021</u>
Advances to suppliers	44,627,252	8,731,932
Withholding taxes	10,387,832	9,519,109
Prepaid expenses	8,705,767	1,877,967
Deposits with others	4,326,706	4,326,706
Employee's custodies	230,581	116,122
Debtors from selling treasury shares	-	84,428,630
Other debtors	3,051,813	6,669,172
	<u>71,329,951</u>	<u>115,669,638</u>

#### 11. Financial assets at amortised cost – Treasury bills

	<u>30 June 2022</u>	<u>31 December 2021</u>
Treasury Bills (Maturity 31 days)	-	-
Treasury bills (Maturity 61 days)	-	498,000,000
<b>Less:</b> Unearned revenue	-	(2,661,940)
	<u>-</u>	<u>495,338,060</u>

The fair value of treasury bills does not differ substantially from the book value, as all maturities of treasury bills are short-term.

#### 12. Cash on hand and at banks

	<u>30 June 2022</u>	<u>31 December 2021</u>
Time deposit	17,809,840	14,871,965
Current accounts	31,808,804	59,993,785
Cash on hand	961,766	1,093,758
<b>Less:</b>		
Cash at banks impairment	(419,006)	(407,575)
	<u>50,161,404</u>	<u>75,551,933</u>

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 12- Cash on hand and at banks (continued)

Movement in the impairment in cash is as follows:

	<u>30 June 2022</u>	<u>31 December 2021</u>	<u>30 June 2021</u>
<b>Balance at the beginning of the period / year</b>	407,575	-	-
The impact of the first adoption standard no.47 "Financial Instruments"	-	1,622,753	1,622,753
Formed during the period / year	11,431	-	-
No longer required during the period / year	-	(1,215,178)	(710,602)
<b>Ending balance at the end of period / year</b>	<u><b>419,006</b></u>	<u><b>407,575</b></u>	<u><b>912,151</b></u>

Current accounts are maintained in banks under the supervision of the Central Bank of Egypt.

The time deposits item includes an amount EGP 17,809,840 on 30 June 2022 (31 December 2021: EGP 14,871,965) are denominated in local banks in US dollars and are payable within one from the date of deposit and are subject to a fixed annual return of 0.5% to 0,75%.

Current accounts deposited in Egyptian Pounds are subject to a fixed annual rate of 7% to 7.5% (31 December 2021: from 6% to 6.5%).

For the purpose of preparation of the cash flow statements, cash and cash equivalents consist of:

	<u>30 June 2022</u>	<u>31 December 2021</u>
Cash and bank balances before deduct the expected credit losses	50,580,410	453,218,359
Treasury bills with maturities dates of 3 months or less	-	46,467,378
Restricted Cash	-	(300,014,787)
Effect of applying new standards	-	(1,622,753)
	<u><b>50,580,410</b></u>	<u><b>198,048,197</b></u>

#### (A) Classification within cash and cash equivalent

Time deposits held at banks presented as cash and cash equivalents if they are due for a period of six months or less from the date of deposit and are repayable with a notice of 24 hours without loss of interest. Treasury bills under cash and cash equivalents have original maturities of no more than six months from the date of acquisition, are easily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

The Company's cash and bank balances are held with reputable financial institutions with credit ratings from Moody's and Standard & Poor's from B to B2.

#### (B) Treasury bills

Investment in treasury bills with a maturity period of one to two months.

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Notes to the interim condensed separate financial statements  
For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**13. Lease liabilities**

The lease liabilities represent the present value of the lease obligations related to lease contracts for buildings, and it was measured at the present value of the contractual lease payments discounted at the incremental borrowing rate of the lessee 11.15%.

	<b>30 June 2022</b>	<b>31 December 2021</b>
<b>The undiscounted value of the lease obligations as follows:</b>		
During the period / year	14,183,881	15,453,191
More than a year	220,102,814	231,977,520
	<b>234,286,695</b>	<b>247,430,711</b>
<b>The present value of the lease obligations as follows:</b>		
During the period / year	14,122,548	13,292,019
More than a year	90,138,051	95,184,292
	<b>104,260,599</b>	<b>108,476,311</b>
	<b>30 June 2022</b>	<b>31 December 2021</b>
Lease liabilities shown as of 31 December 2021	108,476,311	-
The impact of the first adoption standard no. 49 "Lease contracts"	-	111,877,956
Adjustments during the period / year	(3,972,831)	-
Additions during the period / year	-	2,132,532
<b>Lease liabilities on 1 January 2022</b>	<b>104,503,480</b>	<b>114,010,488</b>
<b>Add:</b> Interest formed during the period / year	6,691,015	12,454,626
<b>(Less):</b> Payments during the period / year	(6,933,896)	(17,988,803)
<b>Lease liabilities on 30 June 2022</b>	<b>104,260,599</b>	<b>108,476,311</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 14. Bank Overdraft

The company obtained total credit limits in the form of overdrafts from banks in order to finance working capital at an interest rate of 0.1% in addition to the announced lending rate from the Central Bank. The total available credit limits amounted to 280 million Egyptian pounds and the withdrawn value of these credit limits on 30 June equals nil EGP (31 December 2021: 60,627,560).

#### 15. Creditors and other credit balances

	<u>30 June</u> <u>2022</u>	<u>31 December</u> <u>2021</u>
Suppliers and notes payable	78,783,214	84,035,841
Accrued expenses	64,558,345	59,859,755
Social insurance	2,031,653	1,657,976
Other creditors	13,945,899	13,387,627
	<u>159,319,111</u>	<u>158,941,199</u>

Current trade payables are unsecured and are usually paid within 90 to 120 days of recognition.

#### 16. Operating revenue

	<u>Six months ended 30 June</u>		<u>Three months ended 30</u> <u>June</u>	
	<u>2022</u>	<u>2021</u>	<u>2022</u>	<u>2021</u>
Accommodation and medical supervision revenue	120,246,932	211,922,293	49,201,821	106,374,151
Surgeries revenue	103,132,939	78,070,860	52,456,135	39,496,257
Laboratories revenue	69,377,718	91,537,454	31,378,162	47,137,621
Outpatient clinics revenue	65,377,912	61,216,921	31,825,197	31,138,450
Radiology revenue	41,645,768	48,341,661	18,962,951	24,710,942
Service charge revenue	38,019,686	44,510,097	17,340,432	22,204,449
Cardiac catheterization revenue	31,697,357	35,604,314	16,168,560	17,103,787
Pharmacy revenue	26,361,270	18,922,613	12,688,804	10,292,896
Emergency revenue	24,756,692	22,987,524	12,450,868	12,094,764
Physiotherapy revenue	5,034,063	3,994,704	2,588,264	1,901,813
Cardiac tests revenue	5,027,107	3,924,633	2,408,172	1,922,434
Dentistry revenue	4,379,920	3,681,345	2,118,226	2,241,340
Endoscopy revenue	3,913,792	3,392,709	2,247,229	1,700,574
Revenues from other departments	379,258	409,937	217,318	-
	<u>539,350,414</u>	<u>628,517,065</u>	<u>252,052,139</u>	<u>318,319,478</u>

All types of revenue are recognized at the revenue recognition point in time.

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Notes to the interim condensed separate financial statements  
For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**17. Operating costs**

	<b>Six months ended 30 June</b>		<b>Three months ended 30 June</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Doctors' fees	92,658,785	91,815,767	44,181,022	46,552,704
Salaries, wages and benefits	87,592,355	90,436,259	42,586,473	47,604,897
Medical and pharmaceutical supplies	86,712,411	107,588,707	41,690,896	54,814,193
Fixed assets depreciation	15,671,334	14,351,824	7,899,027	7,257,851
Maintenance, spare parts and energy expenses	14,063,543	11,527,015	7,119,058	5,886,447
Consumables costs	6,978,700	6,916,070	3,164,180	3,418,526
Outsourcing services	5,836,012	7,321,777	2,970,239	2,976,410
Lease amortization	2,608,640	2,351,310	1,304,755	779,120
Rents	2,247,297	2,029,707	1,010,276	1,128,026
Other expenses	6,107,927	11,179,436	2,856,691	5,707,008
	<b>320,477,004</b>	<b>345,517,872</b>	<b>154,782,617</b>	<b>176,125,182</b>

**18. General and administrative expenses**

	<b>Six months ended 30 June</b>		<b>Three months ended 30 June</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Salaries, wages and benefits	62,912,855	48,038,743	31,075,883	23,178,396
Fixed assets depreciation	8,398,271	5,127,715	3,649,790	2,612,445
Professional and consulting fees	8,280,135	7,201,474	4,817,233	3,398,261
Outsourcing services	5,517,277	3,383,674	3,740,674	1,457,365
Maintenance, spare parts and energy expenses	5,251,589	3,239,206	2,431,305	1,420,672
Lease amortization	2,778,931	3,433,071	1,410,336	2,188,298
consumables costs	494,717	398,992	273,833	229,103
Rent	156,557	538,936	29,105	176,105
Other expenses	10,121,757	15,357,606	3,577,840	7,425,731
	<b>103,912,089</b>	<b>86,719,417</b>	<b>51,005,999</b>	<b>42,086,377</b>
Less: the Group's share of the Company's expenses	(29,632,450)	(19,907,261)	(15,735,201)	(8,819,290)
	<b>74,279,639</b>	<b>66,812,156</b>	<b>35,270,798</b>	<b>33,267,087</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 19. Impairment in financial assets

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Trade receivables impairment	2,815,574	18,729,354	1,443,014	12,839,138
Cash in bank impairment	11,431	(710,602)	(14,513)	(630,573)
	<b>2,827,005</b>	<b>18,018,752</b>	<b>1,428,501</b>	<b>12,208,565</b>

#### 20. Earning per share (Basic / Diluted)

The basic share of the profit for the period is calculated by dividing the net profit for the period for the company's shareholders by the weighted average number of shares outstanding during the period after excluding the distribution of employee dividends.

	Six months ended 30 June		Three months ended 30 June	
	2022	2021	2022	2021
Distributable profit	118,081,595	147,522,520	46,776,235	72,962,739
The number of issued shares before the share purchase process	1,600,000,000	1,600,000,000	1,600,000,000	1,600,000,000
Less: the weighted average number of purchased shares (treasury shares)	(58,495,730)	(10,046,667)	(58,495,730)	(10,046,667)
The number of available shares after the share purchase process	1,541,504,270	1,589,953,333	1,541,504,270	1,589,953,333
<b>Earnings per share of the shareholders' share in the net profit for the period</b>	<b>0.08</b>	<b>0.09</b>	<b>0.03</b>	<b>0.05</b>

#### 21. Commitments

##### Capital commitments:

The capital commitments related to fixed assets at financial period end is nothing EGP (31 December 2021: EGP 8,448,002).

## **CLEOPATRA HOSPITAL COMPANY "S.A.E."**

### **Notes to the interim condensed separate financial statements For the six months period ended 30 June 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### **22. Treasury shares**

On February 24, 2022, the board of directors unanimously agreed that the company would purchase treasury shares from the stock market, It was also unanimously agreed that the financing of the purchase process would be self-financing from the company's resources, and that implementation would take place from the session on February 27, 2022, until the implementation of the purchase of treasury shares amounting to a maximum of 10% of the company's total shares, without the participation of any of the main or internal shareholders and their associated groups in accordance with the law.

Based on the of the Board of Directors resolution, the company purchased 127,447,584 of its shares from the stock market for a total amount of 645,888,947 Egyptian pounds, and it was presented by deduction from the equity of treasury shares.

#### **23. Significant changes and subsequent events**

On 13 February 2020, Cleopatra Hospital Company, the River Transport Authority, Nile Badrawi Hospital Company and the heirs of Eng. Hassan Badrawi signed a comprehensive and final settlement agreement, according to which it was agreed to resolve, settle and end all disputes and claims related to the land on which Nile Badrawi Hospital was built. The total settlement amount of EGP 36 million, which falls within the limits of the deducted amounts from the sale price of the shares of Nile Badrawi Hospital in favour of Cleopatra Hospital, a waiver has been agreed upon between each of the River Transport Authority and the Nile Badrawi Hospital Company for the disputes that each raise regarding the land. On 30 March 2021, the Administrative Court issued a ruling accepting the case in form and rejecting it in substance. The Cairo Governorate and the Nile Badrawi Hospital Company appealed the aforementioned ruling before the Supreme Administrative Court, On 21 June 2022 court session determined for both parties to submit the settlement contracts between parties. The consideration of the appeal has been adjourned to its session on November 8, 2022 in order to take measures for the intervention of the heirs of the deceased Hassan Badrawi and to review the notes for whomever he wishes.